Allinaire awarded grant for novel pulmonary treatment

CLEVELAND and INDIANAPOLIS, February 12, 2018 – Allinaire Therapeutics has been awarded a Phase I Small Business Technology Transfer grant from the National Heart, Lung and Blood Institute in the amount of $281,155. This funding will support the development of a novel therapeutic for the treatment of viral-associated lung injury. Allinaire’s aim is to develop new drug therapies for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.

In 2016, Allinaire was formed by BioMotiv, the for-profit drug development accelerator associated with the Harrington Project for Discovery & Development, Indiana University Research & Technology Corp (IURTC), BioCrossroads, and Innovate Indiana. In addition, Allinaire has received several grant awards to support development of its technologies from the Department of Defense and the National Institutes of Health.

Read full press release here

Allinaire Awarded $1.9M in Grant Funding

CLEVELAND and INDIANAPOLIS, September 19, 2017 – Allinaire Therapeutics has been awarded a $1,670,000 Phase II SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) and a $213,000 Discovery Award from the Department of Defense (DOD). 

The funding will support the development of a novel therapeutic for the treatment of respiratory disorders, including acute lung injury; Alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease (COPD).

Allinaire was formed by BioMotiv, a biotech accelerator that is associated with the Harrington Project for Discovery & Development, Indiana University Research & Technology Corp (IURTC), BioCrossroads, and Innovate Indiana.  The company’s lead project is based on technology exclusively licensed from IURTC.

Read full press release here

Take a Deep Breath for an IU Pulmonary Biotech Start-Up

Breathing easy isn't just a euphemism for calming down and taking it easy. It's also the goal of a biotech start-up, Allinaire Therapeutics, which plans to use research from Indiana University School of Medicine to develop new therapies for Chronic Obstructive Pulmonary Disease, or COPD.

Read More